rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Pravin Dugel

Director and Officer

Company insider

Files Form 4 as: Executive Chairman, Ocular Therapeutix; President, IVERIC bio; Director, Whitehawk Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
92
Buys
0
Sells
12
Bought
$0
Sold
$4.9M
Companies
3
Companies where not an officer
1
First trade
20 Jun 2018
Last trade
25 Aug 2026
Last filed
26 Aug 2026

Companies traded

Where they are an officer
OCUL Ocular TherapeutixDirector, Officer · Biotechnology · last 25 Aug 20260 buys · 11 sells
IVERIC bioDirector, Officer · last 11 Jul 20230 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
WHWK Whitehawk TherapeuticsDirector · Biotechnology · last 30 Jun 20210 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
25 Aug 2026filed 26 Aug 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
25 Aug 2026filed 26 Aug 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
25 Aug 2026filed 26 Aug 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
25 Aug 2026filed 26 Aug 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
24 Aug 2026filed 26 Aug 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$233K21,649 at $10.77filing
24 Aug 2026filed 26 Aug 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$233K21,649 at $10.77filing
16 Jun 2026filed 18 Jun 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
16 Jun 2026filed 18 Jun 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
16 Jun 2026filed 18 Jun 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
16 Jun 2026filed 18 Jun 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—50,092 at $0.00filing
28 May 2026filed 28 May 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing
28 May 2026filed 28 May 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing
28 May 2026filed 28 May 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing
28 May 2026filed 28 May 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing
26 May 2026filed 28 May 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$173K21,156 at $8.20filing
26 May 2026filed 28 May 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Sold$173K21,156 at $8.20filing
9 Apr 2026filed 13 Apr 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing
9 Apr 2026filed 13 Apr 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing
9 Apr 2026filed 13 Apr 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing
9 Apr 2026filed 13 Apr 2026OCUL Ocular TherapeutixBiotechnologySEC FORM 4 Code G—394,696 at $0.00filing

Sectors

Health Care11
Not placed1

Buys in green, sells in red, by the company’s sector.

Related people

Todd AndermanChief Legal Officer · Chief Legal Officer at Ocular Therapeutix, filing Form 4 there in the last year
Jeffrey S. HeierChief Scientific Officer · Chief Scientific Officer at Ocular Therapeutix, filing Form 4 there in the last year
Peter KaiserChief Development Officer · Chief Development Officer at Ocular Therapeutix, filing Form 4 there in the last year
Donald NotmanChief Operating Officer · Chief Operating Officer at Ocular Therapeutix, filing Form 4 there in the last year
Sanjay NayakChief Strategy Officer · Chief Strategy Officer at Ocular Therapeutix, filing Form 4 there in the last year